These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23636140)

  • 1. Adherence to targeted oral anticancer medications.
    Geynisman DM; Wickersham KE
    Discov Med; 2013 Apr; 15(83):231-41. PubMed ID: 23636140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.
    Muluneh B; Deal A; Alexander MD; Keisler MD; Markey JM; Neal JM; Bernard S; Valgus J; Dressler LG
    J Oncol Pharm Pract; 2018 Mar; 24(2):98-109. PubMed ID: 27895220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticancer drug adherence].
    Despas F; Roche H; Laurent G
    Bull Cancer; 2013 May; 100(5):473-84. PubMed ID: 23694959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
    Smieliauskas F; Chien CR; Shen C; Geynisman DM; Shih YC
    Pharmacoeconomics; 2014 Jul; 32(7):651-80. PubMed ID: 24821281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.
    Al-Barrak J; Cheung WY
    Support Care Cancer; 2013 Aug; 21(8):2351-7. PubMed ID: 23708821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers.
    Lin C; Clark R; Tu P; Bosworth HB; Zullig LL
    Breast Cancer Res Treat; 2017 Sep; 165(2):247-260. PubMed ID: 28573448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center.
    Canadeo A; Fournogerakis M; Zook F
    Curr Hematol Malig Rep; 2021 Dec; 16(6):509-516. PubMed ID: 34618316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
    Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
    J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
    [No Abstract]   [Full Text] [Related]  

  • 11. Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
    Yeager KA; Waldrop-Valverde D; Paul S; Bruner DW; Klisovic R; Burns E; Mason TA; Patel N; Jennings BM
    Res Nurs Health; 2020 Sep; 43(5):443-452. PubMed ID: 32866350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Provider Adherence to Recommended Monitoring Parameters for Oral Anticancer Medications.
    Redelico TJ; Walton SM; LaFollette J; Adams Curry M; Bernal-Mizrachi L
    J Oncol Pract; 2018 Jul; 14(7):e446-e450. PubMed ID: 29813011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Qualitative Exploration of Medication Experience and Factors Contributing to Adherence to Oral-Targeted Therapy Among Lung Cancer Survivors.
    Liu T; Li N; Liu C; Miao X
    Semin Oncol Nurs; 2022 Dec; 38(6):151352. PubMed ID: 36253304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population.
    Divakaruni A; Saylor E; Duffy AP
    J Oncol Pharm Pract; 2018 Jul; 24(5):337-342. PubMed ID: 28387636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities and challenges in adherence to oral antineoplastic agents.
    Accordino MK; Hershman DL
    Am Soc Clin Oncol Educ Book; 2013; ():271-6. PubMed ID: 23714520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of molecular targeted agents: opportunities for imaging.
    Dancey JE
    Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
    Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
    Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Oral Chemotherapy Nonadherence in Chronic Myeloid Leukemia Patients Using Brief Measures in Community Cancer Clinics: A Pilot Study.
    Davis TC; Arnold CL; Mills G; Lesser GJ; Brown WM; Schulz R; Weaver KE; Pawloski PA
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
    Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
    J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.
    Dean LT; George M; Lee KT; Ashing K
    Cancer; 2020 Aug; 126(16):3606-3612. PubMed ID: 32438466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.